First AD

Second AD

Lia Gore, MD, is section head of Pediatric Hematology/Oncology/BMT, the Ergen Family Chair in Pediatric Oncology, and co-director of the Developmental Therapeutics Program at the University of Colorado Cancer Center, as well as a member of the Colorado Children's Hospital.

Sarah K. Tasian, MD, is chief of the Hematologic Malignancies Program and the Joshua Kahan Endowed Chair in Pediatric Leukemia at the Children’s Hospital of Philadelphia.

Lia Gore, MD, and Sarah K. Tasian, MD, discuss treatment expectations with revumenib in pediatric relapsed/refractory acute leukemia.

Breaking Down Treatment Expectations With Revumenib in Pediatric R/R Acute Leukemia

OncLive News Network®

® video programs provide lively discussions, insights, and expert perspectives on important issues facing today’s cancer care professionals. One variation of the program, titled, 

, comprises live virtual or on-site premium reporting for oncologists as it covers the latest news and information coming out of the largest annual oncology conferences. 

Pediatric Oncology

The OncLive Pediatric Oncology condition center page is a comprehensive resource for clinical news and expert insights on various types of cancers in pediatric patients, including acute lymphoblastic leukemia, acute myeloid leukemia, brain cancers, sarcomas, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in childhood and adolescent and young adult cancers.

Hematologic Oncology

The OncLive Hematology Oncology condition center page is a comprehensive resource for clinical news and expert insights on various hematologic malignancies, including leukemias, lymphomas, myeloproliferative neoplasms, multiple myeloma, and much more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in hematologic cancers.

Breaking Down Treatment Expectations With Revumenib in Pediatric KMT2A+ R/R Acute Leukemia